This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

American Diabetes Association (ADA) 2019 Congress Learnings

To help you support adults with T2DM

Length: 01:36

In this short video, Dr Partha Kar shares his thoughts on the presentation ‘The use of SGLT-2 inhibitors and GLP-1 analogues from a nephrologist’s perspective’ in the treatment of type 2 diabetes from ADA 2019.

Dr. Partha Kar is a consultant in diabetes and endocrinology at Portsmouth Hospitals NHS Trust. He has been the Clinical Director of Diabetes from 2009–2015, being part of a multiple national award-winning department (HSJ Awards/BMJ Awards) due to its services and care provided.

Supporting documentation

STEGLATRO® (ertugliflozin) 5 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

STEGLATRO® (ertugliflozin) 15 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-DIA-00534 | Date of Preparation: July 2019